Categories

Semaglutide Impurities, des-1-His,2-Aib,3-Glu,4-Gly-SMT

The semaglutide impurity des-1-His, 2-Aib, 3-Glu, 4-Gly-SMT is an N-terminal truncated defective body produced during the synthesis or degradation process of semaglutide. Semaglutide is a long-acting GLP-1 analogue widely used in the treatment of type 2 diabetes and obesity. The impurity is characterized by the lack of the first four key amino acid residues at the N-terminus (1-histidine, 2-aminoisobutyric acid, 3-glutamic acid and 4-glycine). This structural deficiency may cause it to lose its GLP-1 receptor binding activity, thereby affecting the efficacy of the drug. In drug development and quality control, such process-related impurities need to be strictly monitored to ensure the purity and therapeutic safety of the final product.

  • Product Details

  • Technical Support

Product Overview

Basic Description

Structure and function:
1. des-1-His,2-Aib,3-Glu,4-Gly-SMT is an impurity of semaglutide, lacking the histidine residue at position 1, the Aib residue at position 2, the glutamic acid residue at position 3, and the glycine residue at position 4.
2. It is a GLP-1 receptor agonist that regulates blood glucose levels by mimicking intestinal secretion of glucagon-like peptide-1 (GLP-1).
3. Due to the lack of multiple amino acid residues, its biological activity and pharmacokinetic properties may be different from those of semaglutide.
In vitro and in vivo studies:
1. In vitro studies have shown that des-1-His,2-Aib,3-Glu,4-Gly-SMT is still able to bind to and activate the GLP-1 receptor, but its affinity and potency may be significantly reduced.
2. In vivo studies have shown that the hypoglycemic effect of this impurity in animal models is weaker than that of semaglutide, and its half-life may be shorter.
3. Preclinical studies have shown that des-1-His,2-Aib,3-Glu,4-Gly-SMT may cause adverse reactions or reduced efficacy in some cases.

​Three-letter sequence​

H-Ala-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2

​Single letter sequence​

HATFTSDVSSYLEGQAAKEFIAWLVKGDVRRAARRRRG-NH2

Molecular formula

C176H266N45O50S

Molecular weight

3798.08 g/mol

Product Attributes

purity

>98%

form

Lyophilized powder

Storage conditions

Store at -20°C/-80°C away from light


Instructions
  • Please store the product immediately according to the recommended conditions in the instructions upon receipt. Unless otherwise specified, all products are freeze-dried powders. Since trace amounts of peptides are deposited in the tube during the freeze-drying process, forming a very thin or invisible peptide layer, we recommend centrifuging at about 8,000-12,000g for 10-30 seconds in a centrifuge before opening the tube cap, so that the peptides attached to the tube cap or tube wall are aggregated at the bottom of the tube.
  • Please refer to relevant literature for the specific optimal working concentration, or explore and optimize through experiments based on the purpose of the experiment and specific cells and animals.
Our company can provide customized synthesis of high-polypeptide, virtual screening of compounds, Animal disease model construction,
Drug safety verification,
Application technology support for gene editing animals, etc.
For specific application consultation, please contact the sales department.

We look forward to your inquiries:

Sales Department 1: Manager Han
Mobile phone: 18701856899
WeChat: 18701856899
QQ: 1295139147
Email: 18701856899@163.com